Principal Financial Group Inc. Trims Stock Holdings in Medpace Holdings, Inc. (NASDAQ:MEDP)

Principal Financial Group Inc. lowered its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 0.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 59,258 shares of the company’s stock after selling 181 shares during the quarter. Principal Financial Group Inc. owned 0.19% of Medpace worth $19,687,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Iron Triangle Partners LP purchased a new stake in shares of Medpace during the third quarter valued at $64,371,000. Wellington Management Group LLP lifted its holdings in Medpace by 36.0% during the 3rd quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after buying an additional 109,886 shares in the last quarter. DF Dent & Co. Inc. boosted its position in Medpace by 189.9% in the 3rd quarter. DF Dent & Co. Inc. now owns 161,298 shares of the company’s stock valued at $53,841,000 after buying an additional 105,659 shares during the period. Caisse DE Depot ET Placement DU Quebec bought a new position in Medpace in the 3rd quarter worth about $23,321,000. Finally, International Assets Investment Management LLC increased its position in shares of Medpace by 38,432.9% during the third quarter. International Assets Investment Management LLC now owns 57,414 shares of the company’s stock worth $19,165,000 after acquiring an additional 57,265 shares during the period. Institutional investors own 77.98% of the company’s stock.

Medpace Stock Up 1.2 %

Medpace stock opened at $344.35 on Tuesday. Medpace Holdings, Inc. has a twelve month low of $302.01 and a twelve month high of $459.77. The business has a fifty day moving average of $343.13 and a two-hundred day moving average of $346.83. The firm has a market cap of $10.49 billion, a P/E ratio of 27.26, a P/E/G ratio of 3.81 and a beta of 1.36.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Equities analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Robert W. Baird boosted their price target on Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a report on Monday, January 27th. Seven equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average price target of $381.44.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.